Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

175.99 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

57 58 Next >

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles ↗

November 10, 2022

Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.

Via Investor's Business Daily

Biogen Names Christopher Viehbacher President and Chief Executive Officer

November 10, 2022

Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies

From Biogen Inc.

Via GlobeNewswire

Elliott Wave Technical Analysis: Biogen Inc. - Thursday, Nov. 10 ↗

November 10, 2022

Looking for a clear three-wave move pullback before considering any long-term longs.

Via Talk Markets

The Power of McKinsey ↗

November 09, 2022

Author Michael Forsythe talks about his new book, "When McKinsey Comes to Town: The Hidden Influence of the World's Most Powerful Consulting Firm."

Via The Motley Fool

Is Biogen Poised for a Bull Run? ↗

November 03, 2022

Biogen has been a market-beating stock this year, but can that trend continue?

Via The Motley Fool

Biogen (BIIB) Q3 2022 Earnings Call Transcript ↗

October 25, 2022

BIIB earnings call for the period ending September 30, 2022.

Via The Motley Fool

Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition ↗

October 25, 2022

Via Benzinga

Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday ↗

November 01, 2022

Mizuho raised Biogen Inc. (NASDAQ: BIIB) price target from $270 to $325. Mizuho analyst Salim Syed maintained the stock with a Buy rating. Biogen shares fell 0.3% to close at $283.44 on Monday.

Via Benzinga

Don't Get Used to Lower Medicare Part B Premiums -- Here's Why ↗

October 29, 2022

Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

October 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review ↗

October 28, 2022

The Dow and S&P 500 moved above a key level while the Nasdaq rose.

Via Investor's Business Daily

Earnings Scheduled For October 25, 2022 ↗

October 25, 2022

Companies Reporting Before The Bell • UBS Gr (NYSE:UBS) is expected to report earnings for its third quarter. • SAP (NYSE:SAP) is expected to report earnings for its third quarter.

Via Benzinga

15 Analysts Have This to Say About Biogen ↗

October 24, 2022

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Via Benzinga

Is Biogen Stock a Buy Now That Guidance Has Been Raised?

October 26, 2022

Biogen stock (NASDAQ:BIIB) continues to get excellent news. On Tuesday, the pharmaceutical company released its third-quarter results, and for the first time in a long time, investors found something...

Via PressReach

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022 ↗

October 26, 2022

Upgrades

Via Benzinga

Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

October 26, 2022

From Biogen Inc.

Via GlobeNewswire

Biogen To Report Q3 Earnings: Here's What To Expect ↗

October 21, 2022

Biogen will report third-quarter 2022 results on Oct 25, before market open.

Via Talk Markets

New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS

October 26, 2022

From Biogen Inc.

Via GlobeNewswire

Is Biogen a Buy After It Boosted Guidance? ↗

October 26, 2022

There's a much bigger story for this biotech than its improved 2022 outlook.

Via The Motley Fool

Biogen Inc. Surpasses Q3 Earnings And Revenue Estimates ↗

October 25, 2022

Biogen Inc. came out with quarterly earnings of $4.77 per share.

Via Talk Markets

Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug ↗

October 25, 2022

Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month.

Via Investor's Business Daily

Recap: Biogen Q3 Earnings ↗

October 25, 2022

Biogen (NASDAQ:BIIB) reported its Q3 earnings results on Tuesday, October 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Biogen beat estimated earnings by...

Via Benzinga

Where Biogen Stands With Analysts ↗

October 24, 2022

Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Biogen Q3 Earnings Preview: Key Items For Investors To Watch ↗

October 24, 2022

Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 24, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today ↗

October 24, 2022

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.47% on an annualized basis producing an average annual return of 9.66%. Currently, Biogen has a market capitalization of...

Via Benzinga

Earnings Preview: Biogen ↗

October 24, 2022

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-10-25. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an...

Via Benzinga

3 Alzheimer's Therapy Stocks to Invest in ↗

October 21, 2022

Alzheimer's treatments could make a big winner of these stocks.

Via The Motley Fool

This Beaten-Down ETF Is Still a Screaming Bear-Market Buy ↗

October 21, 2022

Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.

Via The Motley Fool

Biogen Whale Trades For October 20 ↗

October 20, 2022

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today